Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tazemetostat with Rituximab and Abbreviated Bendamustine in Frontline High Tumor Burden Follicular Lymphoma
NCT05551936Phase 2Active, not recruiting
- Start
- Jan 2023
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tazemetostat in follicular lymphoma (FL). Primary endpoints: Safety and Tolerability at 6 months and Complete Metabolic Response at 2 years. Started Jan 2023; status: active, not recruiting.
02
Drugs
tazemetostat
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT05551936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05551936.